Clinical Trial

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
Protocol Amendment History 1 change
notable Trial sites expanded: 5 -> 9 locations 2026-07-07
Trial Details
NCT Number NCT07300150
Lead Sponsor PAQ Therapeutics, Inc.
Conditions Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
Enrollment 210 participants
Start Date 2025-11-21
Primary Completion 2028-10-18 (estimated)
Study Completion 2028-10-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-06